NEW YORK – Eli Lilly announced on Wednesday that its Phase III LIBRETTO-431 trial for the initial treatment of advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) is now openly enrolling patients. Enrollment will be capped at 400 participants.